How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Microcrystalline Cellulose as Pharmaceutical Excipient Market
- By Application: Tablet Formulation, Capsule Formulation, Suspension Formulation, Granulation, Direct Compression
- By Grade: Pharmaceutical Grade, Food Grade, Cosmetic Grade, Industrial Grade
- By Functionality: Binder, Filler/Diluent, Disintegrant, Lubricant
- By Form: Powder, Granules, Pellets
- By End-Use Industry: Pharmaceuticals, Nutraceuticals, Cosmetics
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Tablet Formulation leads By Application at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 291 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.176 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.184 →
Full report · locked preview
Everything inside the Microcrystalline Cellulose as Pharmaceutical Excipient Market report
A complete, evidence-based study - 12 chapters and 122 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Application 5
Grade 4
Functionality 4
Form 3
End-Use Industry 3
Companies profiled
FMC Corporation (DuPont Nutrition & Health)
JRS Pharma
Asahi Kasei Corporation
Blanver Farmoquímica S.A. de C.V.
Mingtai Chemical Co. Ltd.
MCC Pharma
Domsjö Fabriker AB
Luye Pharma Group
Jubilant Life Sciences
Mingtai Chemical
Fujian Sanming Tianhe Microcrystalline Cellulose Co. Ltd.
Jiangsu Jiuding New Material Technology Co. Ltd.
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →FMC Corporation (DuPont Nutrition & Health)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →JRS Pharma
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Asahi Kasei Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Blanver Farmoquímica S.A. de C.V.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Mingtai Chemical Co. Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →MCC Pharma
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Domsjö Fabriker AB
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Luye Pharma Group
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Jubilant Life Sciences
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Mingtai Chemical
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Fujian Sanming Tianhe Microcrystalline Cellulose Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Jiangsu Jiuding New Material Technology Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Shandong Luwei Pharmaceutical Technology Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →BASF SE
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Ashland Global Holdings Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$5,852M by 2033 · 3.7% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Tablet Formulation38.1
- Capsule Formulation14.3
- Suspension Formulation9.2
- Granulation16.9
- Direct Compression21.4
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,445M → $2,040M · 4.4%
Europe$1,007M → $1,465M · 4.8%
Asia Pacific$919.4M → $1,164M · 3.0%
Latin America$569.2M → $851.9M · 5.2%
Middle East and Africa$437.8M → $553.1M · 3.0%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →3.652026
3.652027
3.662028
3.682029
3.682030
3.712031
3.722032
3.722033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- FMC Corporation (DuPont Nutrition & Health)19.5
- JRS Pharma13.0
- Asahi Kasei Corporation10.0
- Blanver Farmoquímica S.A. de C.V.5.0
- Mingtai Chemical Co. Ltd.12.8
- MCC Pharma11.8
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Application16.2%
Grade25.3%
Functionality12.0%
Form19.8%
End-Use Industry26.6%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.6
- Europe24.1
- Asia Pacific19.2
- Latin America14.0
- Middle East and Africa9.1
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| FMC Corporation (DuPont Nutrition & Health) | 83 | 77 | 78 | 73 | 94 | 88 | 82 |
| JRS Pharma | 77 | 93 | 86 | 86 | 87 | 90 | 87 |
| Asahi Kasei Corporation | 71 | 69 | 62 | 68 | 83 | 68 | 70 |
| Blanver Farmoquímica S.A. de C.V. | 76 | 62 | 63 | 61 | 61 | 73 | 66 |
| Mingtai Chemical Co. Ltd. | 60 | 61 | 55 | 58 | 57 | 54 | 58 |
| MCC Pharma | 62 | 61 | 52 | 67 | 67 | 61 | 62 |
| Domsjö Fabriker AB | 61 | 56 | 50 | 45 | 41 | 64 | 53 |
| Luye Pharma Group | 53 | 56 | 52 | 47 | 37 | 42 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- FMC Corporation (DuPont Nutrition & Health)
- JRS Pharma
- Asahi Kasei Corporation
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| FMC Corporation (DuPont Nutrition & Health) | ✓ | ◐ | ◐ | ◐ | ◐ | ✓ |
| JRS Pharma | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Asahi Kasei Corporation | ◐ | ◐ | − | ◐ | ◐ | ◐ |
| Blanver Farmoquímica S.A. de C.V. | ✓ | ◐ | ◐ | ◐ | − | ◐ |
| Mingtai Chemical Co. Ltd. | − | ◐ | ◐ | ◐ | ◐ | ◐ |
| MCC Pharma | ◐ | ◐ | − | ◐ | − | − |
| Domsjö Fabriker AB | ◐ | − | ◐ | − | − | ◐ |
| Luye Pharma Group | ◐ | ◐ | − | ◐ | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1JRS Pharma87
2FMC Corporation (DuPont Nutrition & Health)82
3Asahi Kasei Corporation70
4Blanver Farmoquímica S.A. de C.V.66
5MCC Pharma62
6Mingtai Chemical Co. Ltd.58
7Domsjö Fabriker AB53
8Luye Pharma Group48
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
FMC Corporation (DuPont Nutrition & Health)JRS Pharma
Challenger1
Strong scale, closing on the leaders.
Asahi Kasei Corporation
Contender3
Focused players with pockets of strength.
Blanver Farmoquímica S.A. de C.V.Mingtai Chemical Co. Ltd.MCC Pharma
Niche2
Specialists in a single segment or region.
Domsjö Fabriker ABLuye Pharma Group
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Application in North America, then scale across Microcrystalline Cellulose as Pharmaceutical Excipient Market — a $93M beachhead inside a $1.38B market.
Beachhead (SOM)$93Mobtainable near-term
Serviceable (SAM)$551Mreachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Tablet Formulation
Best fit — highest urgency & budget in Application.
Economic buyer78 fit
Capsule Formulation
Strong fit — clear ROI and a fast path to value.
End user69 fit
Suspension Formulation
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Application in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Grade & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Functionality
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales49%
Partner / channel27%
Digital / self-serve19%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Application leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Microcrystalline Cellulose as Pharmaceutical Excipient Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified42%
Sales qualified24%
Evaluation13%
Closed-won7%
$19.4KCAC
$102KLTV
5.3:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Microcrystalline Cellulose as Pharmaceutical Excipient Market is a resilient opportunity — $5.56B by 2033, compounding at 4.3%.
TAM · 2025$3.98Btoday
TAM · 2033$5.56Bforecast
CAGR4.3%2027–2033
Cumulative$42.6Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$5.56BTotal addressable market
SAM$2.32BServiceable available market
SOM$426MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →4.3% CAGR
Demand compounds through 2033, outpacing GDP across Application.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Application moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$5.56BLarge & growingTAM by 2033 at 4.3% CAGR
$2.32BServiceable nowreachable with today’s model
$426MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.34BBear2.8% CAGR
$5.56BBase4.3% CAGR
$7.12BBull5.6% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Grade optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Microcrystalline Cellulose as Pharmaceutical Excipient Market — a $7.99B market by 2033. Plan: grow share from 7.3% to 13.3%.
Market size · 2033$7.99Btotal addressable
Market CAGR4.8%2027–2033
Target share13.3%from 7.3% today
Revenue ambition$1.06Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.3% | 13.3% | At risk |
| Revenue | $635M | $1.06B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 33.9% | 45.7% | Behind |
| Customer retention | 91.5% | 96.1% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Application
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Grade capability
A defensible second engine — invest in Grade to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Application share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Grade
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $137M capacity & capability investment
- Greenlight bolt-on M&A in Grade
- Authorise North America expansion plan
- Fund R&D program for Application leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossBehind
- Input-cost & supply riskAhead
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Microcrystalline Cellulose as Pharmaceutical Excipient Market conversation — a $4.85B market you can size, segment and defend in minutes.
Market size · 2033$4.85Btotal opportunity
Growth4.7%CAGR to 2033
Addressable buyers1,728+accounts in scope
Typical ROI6.3×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Application
Goal Grow share in Application
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.3×return on cost, year one
< 2 mopayback period
$63K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
FMC Corporation (DuPont Nutrition & Health)JRS PharmaAsahi Kasei CorporationBlanver Farmoquímica S.A. de C.V.Mingtai Chemical Co. Ltd.MCC PharmaDomsjö Fabriker ABLuye Pharma Group+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Microcrystalline Cellulose as Pharmaceutical Excipient Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Microcrystalline Cellulose as Pharmaceutical Excipient Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Microcrystal Electron Diffraction (MicroED) Service Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportMicro-Computed Tomography System Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportMicro Computed Tomography (Micro CT) Scanner Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportMicro Computed Tomography Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportMicrochips 3D Cell Culture Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportMicrochip Implants Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportMicrochip Electrophoresis System for DNA and RNA Analysis Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportMicro Centrifuge Tubes Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportMicrocentrifuge Tube Rack Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportMicrocentrifuge Spin Column Kits Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportMicrocentrifuge Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportMicrocatheters and Guidewires Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.